Patents by Inventor Hyun-Mi Ju

Hyun-Mi Ju has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated polypeptides used for treatment of inflammatory diseases and inhibiting cancer metastasis
    Patent number: 8530421
    Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX(or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a is pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: September 10, 2013
    Assignee: Supadelixir Inc.
    Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Sun-Hee Lee, Hyun-Mi Ju
  • POLYPEPTIDE OR FUSED PROTEIN THEREOF INHIBITING THE EXTRAVASATION OF WHITE BLOOD CELLS OR THE GROWTH AND/OR METASTASIS OF CANCER CELLS
    Publication number: 20120245091
    Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX (or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: August 24, 2010
    Publication date: September 27, 2012
    Applicant: SUPADELIXIR INC.
    Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Sun-Hee Lee, Hyun-Mi Ju